STENOCARE successfully completes its first harvest without use of pesticides

STENOCARE has successfully completed its first cycle of cultivation and harvest in line with the very strict requirements of the Danish Medical cannabis programme. This includes uniformity of products and zero tolerance for use of pesticides from seed to harvest. STENOCARE’s first harvest of cannabis flowers marks an important milestone for meeting these requirements.

Test production: STENOCARE commenced its indoor cultivation of four different cannabis strains in June 2019, to test and evaluate the individual properties for quality and yield. The first harvest has verified the value of using an indoor cultivation setup, and it has also provided valuable learning about processes and equipment – that will be leveraged as part of the ongoing establishment of the much larger indoor cultivation facility project that is currently under way. The test production harvest is used for laboratory analysis to document strength and pesticide free, active substances and will not be converted into final products.

Objectives met: The first objective was to verify that cultivation without the use of pesticides could be realized – in accordance with the very strict Danish regulatory requirements. These requirements are known to be difficult to meet and are in a class of their own compared to other countries that allow for medical cannabis production. The second objective was to calibrate the equipment to secure uniformity in the various stages from seed to harvest. Both of these objectives have been met and the completion of the first cycle from seed to harvest is an important milestone for the company.

STENOCARE CEO Thomas Skovlund Schnegelsberg comments: “I am pleased to confirm that our indoor cultivation strategy is indeed enabling a highly controllable process without the use of pesticides. Also, I am proud to say that we got it right first time. This is significant, when one considers the many ways that an initial production process can be challenged or even fail”.

Next step: STENOCARE will now continue with the next cultivation cycles to further qualifying cannabis strains for future products and to realize uniformity across repeated harvest batches. The strict Danish regulations require that uniformity is documented with laboratory tests from minimum three unique cultivation cycles. These are the next important milestones on the path to commence the work with the Danish Medicines Agency to have approval to produce finished products for patients. STENOCARE will seek approval for its finished products when quality is documented with uniformity and zero pesticide tolerance laboratory tests from minimum three unique cultivation cycles.

Thomas Skovlund Schnegelsberg, CEO STENOCARE A/S         
Phone: +45 31770060
E-mail: presse@STENOCARE.com

STENOCARE A/S (the Company) was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis Program. The company was the first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis under the Program. STENOCARE is also developing a separate indoor production facility for the cultivation and production of medical cannabis at the Company’s premises in Jutland, Denmark.